10088
document
Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo : a final update . PURPOSE Different outcome results have been published in trials comparing maximal androgen blockade ( MAB ) with chemical or surgical castration alone . The conflicting results could be explained by the fact that patients were included with different prognostic factors . In this new analysis of the Anandron European Study , independent prognostic factors have been evaluated in order to identify those which could influence the study outcome and the impact of the treatment . MATERIAL AND METHODS 399 out of 457 patients recruited in this study were divided in a good or poor prognostic group depending on the presence of two or more poor prognostic factors , these were pain requiring treatment , > 5 bone metastases , hydronephrosis , and alkaline phosphatase > 2 ULN . RESULTS When expressed as a percentage , the improvement in time to progression , overall and cancer specific survival in the Anandron treated patients was identical in both groups . In absolute terms this improvement , however , was greater in the good prognostic group . CONCLUSION In comparison with surgical castration MAB using Anandron , in patients with metastatic prostate cancer improves the time to objective progression , overall and cancer specific survival , irrespective of certain poor prognostic factors .
10089
Intervention_Surgical
castration
10090
Intervention_Pharmacological
anandron
10091
Intervention_Control
placebo
10092
Intervention_Surgical
chemical or surgical castration alone
10093
Intervention_Pharmacological
Anandron
10094
Intervention_Surgical
surgical castration
10095
Intervention_Pharmacological
MAB using Anandron
10096
Outcome_Other
improvement in
10097
Outcome_Physical
time to progression
10098
Outcome_Other
,
10099
Outcome_Mortality
overall and cancer specific survival
10100
Outcome_Physical
objective progression
10101
Outcome_Other
,
10102
Outcome_Mortality
overall and cancer specific survival
10103
Participant_Condition
advanced prostate cancer
10104
Participant_Sample-size
399
10105
Participant_Sample-size
457
10106
Participant_Condition
metastatic prostate cancer